Segulah Medical Acceleration
Investment Details
Investor Type
Private Equity
Asset Class Focus
Private Equity, Venture Capital
Stage Focus
Growth, Early Stage, Series A, Series B
Geographical Focus
United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Austria, Netherlands, Hungary, Portugal, Sweden, Belgium, Norway, Finland, Poland, Czech Republic, Slovakia, Romania, Bulgaria
Industries Focus
- HealthTech
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Medical Research
- Clinical Trials
- Medical Equipment
- Healthcare IT
- Life Science Tools
- Telemedicine
- Medical Software
- Medical Supplies
- Medical Imaging
Investment Size:
2,000,000 to 5,000,000 USD
Investor Details Founded: 2020
Segulah Medical Acceleration (SMA) is a Scandinavian private equity firm dedicated to investing in and developing innovative medical technology companies with global potential. The firm focuses on areas such as medical devices, diagnostics, life science tools, and digital technologies, aiming to bridge the gap between Europe's exceptional research and its full commercialization. SMA's geographic remit includes Scandinavia and other Western European countries, with assets under management totaling approximately SEK 1.3 billion (€125 million equivalent).
SMA's investment strategy targets companies in the growth and early commercialization stages, typically investing between SEK 20 million and SEK 150 million (€2 million to €5 million) per company. The firm emphasizes active ownership, providing strategic guidance and leveraging its extensive network to accelerate the growth and internationalization of its portfolio companies. SMA's team comprises professionals with backgrounds in international investment banking, healthcare, and academia, ensuring a comprehensive approach to supporting its investees.
The firm's portfolio includes companies like Navinci Diagnostics, Signifier Medical Technologies, CytaCoat, and Vidya, reflecting its commitment to advancing medical technologies that address critical global health challenges. SMA's approach integrates environmental, social, and governance (ESG) considerations into its investment process, aligning with the United Nations' Sustainable Development Goals to promote responsible and impactful investing.
Requirements
- Innovative medical technology solutions
- Global market potential
- Strong management teams
- Completed product development
- Active ownership engagement
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Navinci Diagnostics
- Signifier Medical Technologies
- CytaCoat
- Vidya
Mentioned In
-
$19.95
-
$19.95
-
$39.95
-
$245.00
Claim this Investor
Are you an official representative of Segulah Medical Acceleration?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim